非免疫球蛋白配体药物应用进展

doi:10.13523/j.cb.20160213

中国生物工程杂志

2016, Vol. 36

Issue (2): 90-95 DOI: 10.13523/j.cb.20160213

综述

非免疫球蛋白配体药物应用进展

李耿, 刘晓志, 王志明, 高健

华北制药集团新药研究开发有限责任公司抗体药物研制国家重点实验室石家庄 050015

Progress in the Application of Non-immunoglobulin Scaffolds

LI Geng, LIU Xiao-zhi, WANG Zhi-ming, GAO Jian

State Key Laboratory of Antibody Research & Development;New Drug Research and Development Company Ltd., North China Pharmaceutical Corporation, Shijiazhuang 050015, China

全文: PDF(476 KB) HTML

摘要：

同抗体药物相比,非免疫球蛋白配体药物(Non-immunoglobulin scaffolds,非免蛋白配体药物)具有分子量小,不需要翻译后修饰,通常缺乏二硫键,并可进行直接的多聚化修饰等优点。最近几年,研发的非免蛋白配体药物种类就达到了二十余种,如Adhirons,Alphabodies,Centyrins,Pronectins,Repebodies,Affimers,和Obodies等,其中的139个非免疫球蛋白配体,可以特异靶向结合102种蛋白。这些非免疫球蛋白配体多用于癌症和炎症性疾病的治疗和诊断,其中有10多种非免疫球蛋白配体已经进入临床试验研究。最近,非免蛋白配体也被用于伴侣蛋白作结构解析研究,翻译后修饰的细胞内监控,或作为显微镜,流式细胞仪,Western印迹法等检测方法中抗体的替代品。

关键词： 生物技术; 非免疫球蛋白配体药物; 抗体替代品

Abstract:

Compared with the antibody drugs, the non-immune globulin scaffolds with a small molecular weight, do not need to be modified after translation, usually lack disulfide bonds, and can undergo straightforward multimerization. In recent years, the development of non-immune globulin scaffolds have reached more than 20 different types, such as Adhirons, Alphabodies, Centyrins, Pronectins, Repebodies, Affimers, and Obodies. 102 proteins have been specifically targeted by 139 different non-Ig scaffold binders. These non-immune globulin scaffolds are used for the treatment and diagnosis of cancer and inflammatory diseases, and there are more than 10 types of non-immune globulin scaffolds have been used in clinical trials. Recently, non-immune globulin scaffolds have also been used in research as structure determination chaperones, which are used in the study for intracellular monitoring of post-translational modifications or as an alternative to antibodiesfor microscopy, flow cytometry, and Western blotting, and so on.

Key words: Biotechnology Antibody alternatives Non-immunoglobulin scaffolds

收稿日期: 2015-09-11 出版日期: 2015-11-19

ZTFLH:

Q819

基金资助:

国家科技重大专项项目(2012ZX09101313)、河北省重大科技成果转化专项(13042404Z)资助项目

通讯作者: 高健 E-mail: gaojian1972@yahoo.com.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李耿
	刘晓志
	王志明
	高健

引用本文:

李耿, 刘晓志, 王志明, 高健. 非免疫球蛋白配体药物应用进展[J]. 中国生物工程杂志, 2016, 36(2): 90-95.

LI Geng, LIU Xiao-zhi, WANG Zhi-ming, GAO Jian. Progress in the Application of Non-immunoglobulin Scaffolds. China Biotechnology, 2016, 36(2): 90-95.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20160213 或 https://manu60.magtech.com.cn/biotech/CN/Y2016/V36/I2/90

[1] Koerber J T,Hornsby M J,Wells J A.An improved single-chain Fab platform for efficient display and recombinant expression.Journal of Molecular Biology,2015,427(2):576-586.
[2] Skrlec K,Strukelj B,Berlec A.Non-immunoglobulin scaffolds:a focus on their targets.Trends in Biotechnology,2015,33(7):408-418.
[3] Levisson M,Spruijt R B,Winkel I N,et al.Phage display of engineered binding proteins.Methods in Molecular Biology,2014,1129:211-229.
[4] Lee Y,Lee J J,Kim S,et al.Dissecting the critical factors for thermodynamic stability of modular proteins using molecular modeling approach.PloS One,2014,9(5):e98243.
[5] Lin H,Zhou J,Shen L,et al.Biotin-conjugated anti-CD44 antibody-avidin binding system for the improvement of chondrocyte adhesion to scaffolds.Journal of Biomedical Materials Research Part A,2014,102(4):1140-1148.
[6] Helma J,Cardoso M C,Muyldermans S,et al.Nanobodies and recombinant binders in cell biology.The Journal of Cell Biology,2015,209(5):633-644.
[7] Zielonka S,Empting M,Grzeschik J,et al.Structural insights and biomedical potential of IgNAR scaffolds from sharks.mAbs,2015,7(1):15-25.
[8] Liang S I,McFarland J M,Rabuka D,et al.A modular approach for assembling aldehyde-tagged proteins on DNA scaffolds.Journal of the American Chemical Society,2014,136(31):10850-10853.
[9] Maltezos A,Platis D,Vlachakis D,et al.Design,synthesis and application of benzyl-sulfonate biomimetic affinity adsorbents for monoclonal antibody purification from transgenic corn.Journal of Molecular Recognition,2014,27(1):19-31.

[1]	刘旭霞,杨安珂. 美国SECURE规则评析及其对中国的启示[J]. 中国生物工程杂志, 2021, 41(9): 126-135.
[2]	胡鸢雷,陈彦丞,濮润,姚卫浩,张宏翔. 英国生物技术产业创新创业生态系统的构建与启示[J]. 中国生物工程杂志, 2021, 41(4): 100-105.
[3]	吴函蓉,王莹,黄英明,李冬雪,李治非,方子寒,范玲. 以基地平台为抓手,促进生物技术创新与转化[J]. 中国生物工程杂志, 2021, 41(12): 141-147.
[4]	吴函蓉,王莹,杨力,葛瑶,范玲. 我国生物技术基地平台现状与发展建议[J]. 中国生物工程杂志, 2021, 41(11): 119-123.
[5]	吴函蓉,王莹,李苏宁,桑晓冬,范玲. 我国生物技术基地平台建设政策研究[J]. 中国生物工程杂志, 2021, 41(10): 127-131.
[6]	宋以梅,贾秀伟,李树标,高翠娟. 工业微生物解脂耶氏酵母及其应用研究^*[J]. 中国生物工程杂志, 2020, 40(9): 77-86.
[7]	胡鸢雷,姚卫浩,濮润,张宏翔. 美国创新创业生态系统中生物技术孵化器的作用[J]. 中国生物工程杂志, 2019, 39(12): 103-109.
[8]	赵萍,张博,王学昭. 农业生物技术领域专利态势分析[J]. 中国生物工程杂志, 2018, 38(8): 100-107.
[9]	陈方,陈云伟,丁陈君,郑颖,吴晓燕,罗丹丹,赵秋伟,于波. “一带一路”沿线国家生物技术发展趋势研究[J]. 中国生物工程杂志, 2018, 38(1): 1-14.
[10]	沈平, 武玉花, 梁晋刚, 卢新, 章秋艳, 王颢潜, 刘鹏程. 转基因作物发展及应用概述[J]. 中国生物工程杂志, 2017, 37(1): 119-128.
[11]	陈方, 丁陈君, 陈云伟, 郑颖, 邓勇, 徐萍, 于建荣, 吴林寰, 马俊才, 曾艳, 刘斌. 中国工业生物技术发展态势分析与展望[J]. 中国生物工程杂志, 2016, 36(5): 1-11.
[12]	王凯, 张威, 李师翁. 植酸酶及其应用[J]. 中国生物工程杂志, 2015, 35(9): 85-93.
[13]	毛开云, 杨露, 王恒哲, 陈大明. 生物技术药物市场现状与发展趋势[J]. 中国生物工程杂志, 2015, 35(1): 111-119.
[14]	高凯, 任跃明, 王兰, 郭中平, 王军志. 关于我国药典重组DNA技术产品总论的思考[J]. 中国生物工程杂志, 2014, 34(5): 107-115.
[15]	高教琪, 韩锡铜, 孔亮, 袁文杰, 王娜, 白凤武. 马克斯克鲁维酵母在工业生物技术中的应用[J]. 中国生物工程杂志, 2014, 34(2): 109-117.

Viewed

Full text

Abstract

Cited

Shared

Discussed